Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Vascular endothelial growth factor receptor VEGFR

Compound 57 has been identified as a vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor of interest for the treatment of cancer <20030PD676>. [Pg.329]

Epidermal growth factor receptor (EGFR) Fibroblast growth factor receptor (FGFR) Vascular endothelial growth factor receptor (VEGFR)... [Pg.385]

Eskens FA et al (2006) The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors a review. Eur J Cancer 42 3127-3139... [Pg.243]

FLK-1 Vascular endothelial growth factor receptor (VEGFR)... [Pg.9]

Note of worth is also the successful replacement of the methyl ester with oxime ethers and Af-methoxy imidoyl nitrile in the design of muscarinic agonists (Figure 15.28). Several 1,2,4-oxadiazoles and the other five-mem-bered heterocycles are employed also for other therapeutic indications like monoamine transporter and opioid receptors,5-HT agonists, bradykinin Bi receptor antagonists, and vascular endothelial growth factor receptor (VEGFR-2) inhibitors. ... [Pg.312]

In addition to imatinib, some inhibitors of receptor tyrosine kinases targeting epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR) have been found to have antitumor and/or other activities. [Pg.416]

Pazopanib The effect of ketoconazole on the pharmacokinetics and safety of pazopanib, an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2 and VEGFR-3), platelet-derived growth factor receptors (PDGFR-a and PDGFR-b) and c-kit was evaluated in 21 patients [59 ]. and AUC increased 42% and 40%, respectively. [Pg.388]

Optimization of the large (MW = 512), lipophilic (clogP = 7.6), and very potent (Kj = 0.22 nM) Vascular Endothelial Growth Factor Receptor Tyrosine Kinase (VEGFR TK) inhibitor 8 (LLE = 2.1) to produce the development candidate axitinib (9) was recently reported [17]. [Pg.390]


See other pages where Vascular endothelial growth factor receptor VEGFR is mentioned: [Pg.131]    [Pg.553]    [Pg.422]    [Pg.422]    [Pg.13]    [Pg.176]    [Pg.1192]    [Pg.469]    [Pg.506]    [Pg.544]    [Pg.190]    [Pg.364]    [Pg.55]    [Pg.286]    [Pg.381]    [Pg.1192]    [Pg.249]    [Pg.434]    [Pg.4]    [Pg.125]    [Pg.14]    [Pg.102]    [Pg.407]    [Pg.407]    [Pg.4]    [Pg.131]    [Pg.64]    [Pg.339]    [Pg.84]    [Pg.195]    [Pg.247]    [Pg.360]    [Pg.553]    [Pg.310]    [Pg.771]    [Pg.781]   
See also in sourсe #XX -- [ Pg.2 , Pg.131 ]




SEARCH



Endothelial

Endothelial growth factors

Endothelialization

Growth factors receptors

Growth receptor

VEGFR

VEGFR-2, Vascular endothelial growth factor

Vascular endothelial growth

Vascular endothelial growth factor receptor

Vascular endothelial growth factor receptor VEGFR) inhibitors

Vascular growth

Vascular receptor

© 2024 chempedia.info